OPKO Health Valuation
Is 0KCS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0KCS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0KCS ($1.56) is trading below our estimate of fair value ($10.71)
Significantly Below Fair Value: 0KCS is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0KCS?
Key metric: As 0KCS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0KCS's PS Ratio? | |
|---|---|
| PS Ratio | 1.5x |
| Sales | US$711.41m |
| Market Cap | US$1.06b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.7x |
| Enterprise Value/EBITDA | -5.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0KCS's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.6x | ||
IDHC Integrated Diagnostics Holdings | 2.4x | 19.1% | US$220.9m |
CUSH CRUSHMETRIC Group | 42.8x | n/a | UK£30.0m |
TLY Totally | 0.2x | 3.1% | UK£17.1m |
KOO Kooth | 1.1x | 9.4% | UK£59.5m |
0KCS OPKO Health | 1.5x | 6.8% | US$1.1b |
Price-To-Sales vs Peers: 0KCS is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (11.6x).
Price to Sales Ratio vs Industry
How does 0KCS's PS Ratio compare vs other companies in the European Healthcare Industry?
| 7 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 7 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 0KCS is expensive based on its Price-To-Sales Ratio (1.5x) compared to the European Healthcare industry average (0.6x).
Price to Sales Ratio vs Fair Ratio
What is 0KCS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.5x |
| Fair PS Ratio | 0.6x |
Price-To-Sales vs Fair Ratio: 0KCS is expensive based on its Price-To-Sales Ratio (1.5x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$1.56 | US$3.96 +153.6% | 56.8% | US$8.50 | US$2.00 | n/a | 6 |
| Nov ’25 | US$1.52 | US$3.96 +160.3% | 56.8% | US$8.50 | US$2.00 | n/a | 6 |
| Oct ’25 | US$1.49 | US$3.96 +165.7% | 56.8% | US$8.50 | US$2.00 | n/a | 6 |
| Sep ’25 | US$1.68 | US$3.96 +135.5% | 56.8% | US$8.50 | US$2.00 | n/a | 6 |
| Aug ’25 | US$1.36 | US$3.83 +181.8% | 61.5% | US$8.50 | US$1.50 | n/a | 6 |
| Jul ’25 | US$1.23 | US$4.25 +245.6% | 53.8% | US$8.50 | US$1.50 | n/a | 6 |
| Jun ’25 | US$1.41 | US$4.25 +201.4% | 53.8% | US$8.50 | US$1.50 | n/a | 6 |
| May ’25 | US$1.23 | US$4.25 +245.4% | 53.8% | US$8.50 | US$1.50 | n/a | 6 |
| Apr ’25 | US$1.21 | US$4.25 +251.4% | 53.8% | US$8.50 | US$1.50 | n/a | 6 |
| Mar ’25 | US$1.00 | US$4.25 +324.8% | 53.8% | US$8.50 | US$1.50 | n/a | 6 |
| Feb ’25 | US$1.01 | US$4.33 +329.2% | 50.6% | US$8.50 | US$2.00 | n/a | 6 |
| Jan ’25 | US$1.53 | US$4.42 +188.8% | 48.2% | US$8.50 | US$2.00 | n/a | 6 |
| Dec ’24 | US$1.52 | US$4.42 +190.7% | 48.2% | US$8.50 | US$2.00 | n/a | 6 |
| Nov ’24 | US$1.24 | US$4.48 +261.5% | 48.0% | US$8.50 | US$2.00 | US$1.52 | 6 |
| Oct ’24 | US$1.58 | US$4.48 +183.8% | 48.0% | US$8.50 | US$2.00 | US$1.49 | 6 |
| Sep ’24 | US$1.82 | US$4.48 +146.4% | 48.0% | US$8.50 | US$2.00 | US$1.68 | 6 |
| Aug ’24 | US$1.87 | US$4.32 +131.0% | 49.7% | US$8.50 | US$2.00 | US$1.36 | 6 |
| Jul ’24 | US$2.20 | US$4.32 +96.7% | 49.7% | US$8.50 | US$2.00 | US$1.23 | 6 |
| Jun ’24 | US$1.37 | US$4.78 +249.3% | 43.0% | US$8.50 | US$3.00 | US$1.41 | 5 |
| May ’24 | US$1.45 | US$4.85 +234.9% | 43.0% | US$8.50 | US$3.00 | US$1.23 | 5 |
| Apr ’24 | US$1.46 | US$4.85 +233.3% | 43.0% | US$8.50 | US$3.00 | US$1.21 | 5 |
| Mar ’24 | US$1.16 | US$4.85 +319.9% | 43.0% | US$8.50 | US$3.00 | US$1.00 | 5 |
| Feb ’24 | US$1.39 | US$4.95 +256.6% | 40.5% | US$8.50 | US$3.00 | US$1.01 | 5 |
| Jan ’24 | US$1.19 | US$4.95 +315.3% | 40.5% | US$8.50 | US$3.00 | US$1.53 | 5 |
| Dec ’23 | US$1.47 | US$5.44 +271.2% | 36.0% | US$8.50 | US$3.50 | US$1.52 | 4 |
| Nov ’23 | US$1.91 | US$5.69 +197.8% | 30.7% | US$8.50 | US$4.00 | US$1.24 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Centene
US$30.5b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
0HVB
US$60.61
7D
5.4%
1Y
-18.2%
Elevance Health
US$93.6b
Operates as a health benefits company in the United States.
0HG8
US$402.69
7D
0.2%
1Y
-15.8%
Kooth
UK£59.5m
Provides digital mental health services to children, young people, and adults in the United Kingdom.
KOO
UK£1.65
7D
1.5%
1Y
-45.2%